Factors Associated With Developing Neurocognitive Adverse Events in Patients Receiving Lorlatinib After Progression on Other Targeted Therapies
- Resource Type
- Article
- Source
- In
Journal of Thoracic Oncology January 2023 18(1):67-78 - Subject
- Language
- ISSN
- 1556-0864